The Online Investor
YM Biosciences Inc (YMI)

YM Biosciences is a biopharmaceutical company engaged in the development of products primarily for the treatment of patients with cancer. Co. conducts and out-sources clinical trials and out-sources the manufacture of clinical materials to third parties. Co. has three product candidates in the clinical stage of development: CYT387, a small molecule pyrimidine kinase inhibitor is used to develop drugs for the inhibition of the JAK2 enzyme; NIMOTUZUMAB, a humanized monoclonal antibody, designed to treat epithelial cancers; and CYT997, a small molecule microtubule polymerization inhibitor, is being developed for the treatment of solid and other tumors in cancer patients.
Company Name: 
YM Biosciences Inc
Website: 
www.ymbiosciences.com
Sector: 
Biotechnology
Quotes delayed 20 minutes

Email EnvelopeFree YMI Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.72 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

YM Biosciences Inc (YMI) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.